CAROL FABIAN

Summary

Affiliation: University of Kansas Medical Center
Country: USA

Publications

  1. doi request reprint Simplifying the energy balance message for breast cancer prevention
    Carol J Fabian
    University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 1102, Westwood, KS 66205, USA
    Cancer Prev Res (Phila) 5:511-4. 2012
  2. pmc Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer
    Qamar J Khan
    University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA
    Breast Cancer Res 9:R35. 2007
  3. ncbi request reprint Breast-tissue sampling for risk assessment and prevention
    C J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KA 66160, USA
    Endocr Relat Cancer 12:185-213. 2005
  4. ncbi request reprint Reduction in proliferation with six months of letrozole in women on hormone replacement therapy
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Breast Cancer Res Treat 106:75-84. 2007
  5. ncbi request reprint Mammographic density: use in risk assessment and as a biomarker in prevention trials
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Nutr 136:2705S-8S. 2006
  6. pmc Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas 66160 7418, USA
    Cancer Prev Res (Phila) 3:1342-50. 2010
  7. ncbi request reprint Use of biomarkers for breast cancer risk assessment and prevention
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    J Steroid Biochem Mol Biol 106:31-9. 2007
  8. pmc The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
    C J Fabian
    Breast Cancer Prevention Center, Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160 7418, USA
    Int J Clin Pract 61:2051-63. 2007
  9. ncbi request reprint Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint
    CAROL FABIAN
    University of Kansas, 3901 Rainbow Boulevard, Kansas City, KS 66160 7820, USA
    Cancer Epidemiol Biomarkers Prev 16:2210-2. 2007
  10. ncbi request reprint Selective estrogen-receptor modulators for primary prevention of breast cancer
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    J Clin Oncol 23:1644-55. 2005

Detail Information

Publications42

  1. doi request reprint Simplifying the energy balance message for breast cancer prevention
    Carol J Fabian
    University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 1102, Westwood, KS 66205, USA
    Cancer Prev Res (Phila) 5:511-4. 2012
    ....
  2. pmc Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer
    Qamar J Khan
    University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA
    Breast Cancer Res 9:R35. 2007
    ..It is not known whether there is a correlation between mammographic density and Ki-67 expression in benign breast ductal cells obtained by RPFNA...
  3. ncbi request reprint Breast-tissue sampling for risk assessment and prevention
    C J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KA 66160, USA
    Endocr Relat Cancer 12:185-213. 2005
    ..However, ductal lavage, RPFNA and random and directed core needle biopsies are all being utilized in ongoing multi-institutional Phase II studies. The strengths and weaknesses of each method are reviewed...
  4. ncbi request reprint Reduction in proliferation with six months of letrozole in women on hormone replacement therapy
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Breast Cancer Res Treat 106:75-84. 2007
    ..Given the dramatic reduction in proliferation, the effect of letrozole on risk and response biomarkers should be explored further in a randomized, placebo-controlled Phase IIB breast cancer chemoprevention trial...
  5. ncbi request reprint Mammographic density: use in risk assessment and as a biomarker in prevention trials
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Nutr 136:2705S-8S. 2006
  6. pmc Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas 66160 7418, USA
    Cancer Prev Res (Phila) 3:1342-50. 2010
    ..035) was also observed. Based on favorable risk biomarker modulation and lack of adverse events, we are initiating a randomized trial of SDG versus placebo in premenopausal women...
  7. ncbi request reprint Use of biomarkers for breast cancer risk assessment and prevention
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    J Steroid Biochem Mol Biol 106:31-9. 2007
    ..At the present time these biomarkers may not be used to predict or monitor individual response to standard prevention interventions but are used in early phase clinical trials as preliminary indicators of efficacy...
  8. pmc The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
    C J Fabian
    Breast Cancer Prevention Center, Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160 7418, USA
    Int J Clin Pract 61:2051-63. 2007
    ..an AI for risk reduction and (ii) recognise and manage AI-associated adverse events. The primary purpose of this review is to help internists with these two tasks...
  9. ncbi request reprint Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint
    CAROL FABIAN
    University of Kansas, 3901 Rainbow Boulevard, Kansas City, KS 66160 7820, USA
    Cancer Epidemiol Biomarkers Prev 16:2210-2. 2007
  10. ncbi request reprint Selective estrogen-receptor modulators for primary prevention of breast cancer
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    J Clin Oncol 23:1644-55. 2005
  11. ncbi request reprint Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator
    Carol J Fabian
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Clin Cancer Res 10:5403-17. 2004
    ..We performed a multi-institutional evaluation of arzoxifene in women with newly diagnosed ductal carcinoma in situ or T1/T2 invasive cancer...
  12. pmc Breast cancer chemoprevention: beyond tamoxifen
    C J Fabian
    University of Kansas Medical Center, Kansas City, Kansas 66160 7320, USA
    Breast Cancer Res 3:99-103. 2001
    ..If validated, morphological and molecular markers could eventually replace cancer incidence as an indicator of efficacy in future phase III trials...
  13. ncbi request reprint Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model
    C J Fabian
    Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City 66160 7820, USA
    J Natl Cancer Inst 92:1217-27. 2000
    ....
  14. ncbi request reprint A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers
    Carol J Fabian
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Clin Cancer Res 8:3105-17. 2002
    ..Subjects were randomized to 6 months of oral DFMO (0.5 g/m(2)/day) or placebo, followed by repeat fine-needle aspiration and biomarker assessment. The main study end point was an improvement in cytologic pattern...
  15. ncbi request reprint Chemoprevention for high-risk women: tamoxifen and beyond
    C J Fabian
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Breast J 7:311-20. 2001
    ..A number of agents are being developed that target molecular abnormalities in IEN, have fewer or different side effects than tamoxifen, and may be effective in ER-negative or tamoxifen-resistant disease...
  16. ncbi request reprint Breast cancer chemoprevention: current challenges and a look toward the future
    Carol J Fabian
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Clin Breast Cancer 3:113-24. 2002
    ....
  17. ncbi request reprint Chemoprevention of breast cancer: implications for postmenopausal women
    Carol J Fabian
    Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas 66160 7820, USA
    Drugs Aging 19:43-78. 2002
    ....
  18. ncbi request reprint Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention
    C J Fabian
    University of Kansas Medical Center, Kansas City 66160 7320, USA
    Ann N Y Acad Sci 952:44-59. 2001
    ..Sample Phase I and Phase II clinical trial designs are reviewed using modulation of molecular markers and breast intraepithelial neoplasia as the major endpoints...
  19. ncbi request reprint Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration
    Qamar J Khan
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    Cancer Epidemiol Biomarkers Prev 14:786-9. 2005
    ..The association of Ki-67 expression with cytologic atypia, a known risk factor for development of breast cancer, provides preliminary justification for its use as a response biomarker in phase II chemoprevention trials...
  20. ncbi request reprint Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score
    Priyanka Sharma
    Department of Internal Medicine, Division of Hematology Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Breast Cancer Res Treat 100:71-6. 2006
    ..Estrogen receptor (ER) expression in breast epithelial cells has potential as a risk marker for development of breast cancer and as a response marker for preventive interventions...
  21. ncbi request reprint Characterization of a preclinical model of simultaneous breast and ovarian cancer progression
    Alison Y Ting
    Breast Cancer Prevention Center, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Carcinogenesis 28:130-5. 2007
    ..This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies...
  22. ncbi request reprint Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer
    Carola M Zalles
    Department of Pathology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Breast Cancer Res Treat 97:191-7. 2006
    ..RPFNA was more likely to yield an evaluable specimen, but if a cellular DL specimen was obtained, morphology was generally similar...
  23. ncbi request reprint Optimization of estrogen receptor analysis by immunocytochemistry in random periareolar fine-needle aspiration samples of breast tissue processed as thin-layer preparations
    Brian K Petroff
    Breast Cancer Prevention Center, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Appl Immunohistochem Mol Morphol 14:360-4. 2006
    ....
  24. doi request reprint Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer
    Qamar J Khan
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
    Breast Cancer Res Treat 119:111-8. 2010
    ..Vitamin D3 supplementation with 50,000 IU per week is safe, significantly increases 25OHD levels, and may reduce disability from AI-induced arthralgias...
  25. ncbi request reprint Detection of biomarker gene expression by real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed random periareolar fine needle aspirates of human breast tissue
    Brian K Petroff
    Breast Cancer Prevention Center, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Anal Quant Cytol Histol 28:297-302. 2006
    ....
  26. doi request reprint The relationship between vitamin D and breast cancer incidence and natural history
    Qamar J Khan
    University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 1104, Westwood, KS, 66205, USA
    Curr Oncol Rep 12:136-42. 2010
    ..A recent report also suggests that vitamin D may reduce breast cancer recurrence and mortality. Finally, vitamin D is being investigated as a means to reduce aromatase inhibitor-induced joint symptoms...
  27. ncbi request reprint Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count
    Ossama Tawfik
    Department of Pathology and Laboratory Medicine, Kansas University Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Virchows Arch 450:627-36. 2007
    ..Distinction among the different histologic grades for overall survival curves was better indicated by the N+P than the SBR system...
  28. ncbi request reprint Failure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimens
    Priyanka Sharma
    Department of Internal Medicine, Division of Hematology Oncology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Breast Cancer Res Treat 87:59-64. 2004
    ..Evidence of hyperplasia with atypia found both on random periareolar fine needle aspiration (RPFNA) and in nipple aspirate fluid (NAF) fluid are associated with an increased risk for breast cancer...
  29. pmc Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases
    Alison Y Ting
    Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Cancer Prev Res (Phila) 1:546-53. 2008
    ..Our study suggests that tamoxifen prevents early progression to mammary cancer but has no effect on ovarian cancer progression in this rat model...
  30. ncbi request reprint Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens
    Robert J Ellis
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City 66160, USA
    Breast Cancer Res Treat 71:95-102. 2002
    ..These results may be helpful for designing possible future trials that evaluate the assay's role in adjuvant chemotherapy selection...
  31. ncbi request reprint Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial
    Jennifer R Klemp
    University of Kansas Breast Cancer Prevention Center, Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, Kansas 66160 7418, USA
    Fam Cancer 4:279-84. 2005
    ....
  32. ncbi request reprint Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration
    Gregory R Bean
    Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 14:790-8. 2005
    ..Results from this study indicate that the RARbeta2 P2 promoter is frequently methylated (69%) in primary breast cancers and shows a positive association with increasing cytologic abnormality in RPFNA...
  33. ncbi request reprint Ductal lavage for early detection--what doesn't come out in the wash
    Carol J Fabian
    J Natl Cancer Inst 96:1488-9. 2004
  34. ncbi request reprint Low-dose tamoxifen for combination hormone replacement therapy users
    Carol J Fabian
    J Clin Oncol 25:4162-4. 2007
  35. ncbi request reprint Is there a future for ductal lavage?
    Carol J Fabian
    Clin Cancer Res 13:4655-6. 2007
  36. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
    ..The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer...
  37. ncbi request reprint Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk
    Gregory R Bean
    Duke University Medical Center, Box 2628, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 16:50-6. 2007
    ....
  38. ncbi request reprint Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration in women at high risk for breast cancer
    Peter H Bartels
    Optical Sciences Center, Division of Epidemiology and Biostatistics, Department of Medicine, University of Arizona, Tucson, Arizona, USA
    Anal Quant Cytol Histol 29:63-70. 2007
    ..To establish whether karyometry was likely to detect change in the proportion of abnormal cells in random periareolar fine needle aspiration (RPFNA) specimens from high-risk women in a 6-month prevention trial with an aromatase inhibitor...
  39. ncbi request reprint Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration
    Deepa Bhandare
    Cancer Epidemiol Biomarkers Prev 14:2278; author reply 2278-9. 2005
  40. ncbi request reprint Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF
    Gregory R Bean
    Duke University Medical Center, Durham, NC 27710, USA
    Clin Cancer Res 13:6834-41. 2007
    ..These data suggest that cells that lack p16(INK4a) activity would be at high risk for breast cancer development and may exhibit an increased frequency of DNA methylation events in early cancer...
  41. ncbi request reprint Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO
    David M Euhus
    The University of Texas Southwestern Medical Center at Dallas, 75390 9155, USA
    J Natl Cancer Inst 94:844-51. 2002
    ..We measured the performance of eight cancer risk counselors and of a computer model, BRCAPRO, at identifying families likely to carry a BRCA gene mutation...
  42. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...

Research Grants8

  1. Breast Cancer Prevention by Letrozole in High Risk Women
    Carol J Fabian; Fiscal Year: 2010
    ....
  2. CHEMOPREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER
    CAROL FABIAN; Fiscal Year: 2003
    ..The answer impacts on the entire future of breast cancer chemoprevention development efforts. ..
  3. Breast Cancer Risk Biomarkers and Energy Balance
    CAROL FABIAN; Fiscal Year: 2007
    ..The results of this study will potentially lead to a larger controlled trial to document the beneficial effects of exercise/diet/behavioral modification on risk factors for breast cancer development and all cause mortality. ..
  4. FlaxSeed Lignan for Breast Cancer Chemoprevention
    CAROL FABIAN; Fiscal Year: 2007
    ..If positive, the results of this study will be critical to the design and implementation of a placebo-controlled Phase II prevention trial with Brevail and/or commercial flaxseed. ..
  5. Breast Cancer Prevention by Letrozole in High Risk Women
    CAROL FABIAN; Fiscal Year: 2007
    ....
  6. Breast Cancer Prevention by Letrozole in High Risk Women
    CAROL FABIAN; Fiscal Year: 2009
    ....